Chronic Hypoparathyroidism-Current and Emerging Therapies.

Area of Science:

• Endocrinology
• Pharmacology

Background:

• Hypoparathyroidism (HypoPT) is a rare endocrine disorder causing low serum calcium due to insufficient parathyroid hormone (PTH).
• Conventional treatments (calcium, activated vitamin D) have limitations, including poor symptom control and high pill burden.
• Current PTH replacement therapies have short half-lives or production issues.

Purpose of the Study:

• To review the current landscape of hypoparathyroidism treatment.
• To highlight the advancements in parathyroid hormone replacement therapy.
• To discuss emerging therapies for hypoparathyroidism.

Main Methods:

• Review of existing literature on hypoparathyroidism treatments.
• Analysis of clinical trial data for novel therapeutic agents.
• Discussion of approved and investigational therapies.

Main Results:

• Palopegteriparatide, a long-acting PTH analog, is approved and demonstrates efficacy in maintaining eucalcemia, lowering urinary calcium and phosphate, and reducing pill burden.
• Other emerging therapies like eneboparatide, encalaret, oral PTH1 receptor agonists, and weekly PTH formulations are in various stages of clinical development.
• These novel therapies aim to provide more physiological and convenient treatment options.

Conclusions:

• Palopegteriparatide represents a significant advancement in hypoparathyroidism management.
• Ongoing research and development are yielding promising new therapeutic avenues for hypoparathyroidism.
• The future of hypoparathyroidism treatment involves more targeted and effective PTH-based or related therapies.